Andrea Berardi

Part of Sanofi, Imtix is a French company that develops and markets pharmaceuticals for transplantation. The company is based in Lyon, France. The company was founded by Gilles Alberici. Imtix was acquired by SangStat Medical Corp. from Rhone-Poulenc SA on October 01, 1998 for $31 million.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Humabs BioMed SA is an antibody therapeutics biotechnology company. It develops human monoclonal antibody platforms for treatment of infectious and inflammatory diseases. The company was founded by Prof. Antonio Lanzavecchia on October 24, 2011 and is headquartered in Bellinzona, Switzerland.

National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC.

Pentagram Wealth Management SA provides wealth management services. The private company is based in Lugano, Switzerland.

The Institute for Research in Biomedicine provides research and development services in the field of biomedicine.

Adienne SRL manufactures pharmaceutical products. It offers drug products for oncohematology, autoimmune diseases, and bone marrow transplantation. The company was founded in 2004 and is headquartered in Caponago, Italy.

Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.

Octalfa SAS is a family-owned, independent private equity holding and investment company controlled by Gilles Alberici. Octalfa was established in 2006 and is based near Lyon in Eastern France. The firm manages a portfolio of participations in Life Sciences companies. They are also the key investor of Octalfa 360 Health and Green Technologies, a sector mutual fund invested in listed equity, co-managed by 360 Asset Managers SA and Xénia SARL (aka Xénia Gestion Privée). The fund focuses on sectors such as biotechnology and clean technology. Octalfa is committed to public health issues, and established the Dominique Alberici-Octalfa Corporate Foundation to support initiatives aimed at improving medical and paramedical care for cancer patients and the disabled.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Orega Biotech SAS provides monoclonal antibody-based immunotherapy for cancer patients. It specializes in the discovery of novel targets and the development of first-in-class monoclonal antibodies for the treatment of cancer. The company was founded by Gilles Alberici, Nathalie Bonnefoy, Jean-François Eliaou, and Armand Bensussan in 2010 and is headquartered in Écully, France.

Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.

Polyplus-transfection SA develops and sells solutions for the delivery of nucleic acids in research, bio production, and therapeutics. Its products are transfection reagents and trademarks, mainly for gene and cell therapies. The company was founded by Jean-Paul Behr, Anne-Lise Monjanel, Joelle Bloch, and Patrick Metz in January 2001 and is headquartered in Illkirch-Graffenstaden, France.

EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France.

ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Jazz Pharmaceuticals II SASU engages in the development of biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases. Its lead assets are pegcrisantaspase (Asparec), a PEGylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. The company was founded in 2008 and is headquartered in Ecully, France.